MS Validated Antibodies
Many antibody vendors provide very little information and images on how an antibody stains. References are often limited to a positive and a negative control on their website. When pathologists and researchers use these antibodies, they don’t know about the complete staining behaviour of an antibody because often they do not have time or access to enough different tissues to conduct an in-house validation of the antibody. This can cause severe problems because researchers cannot know if they can trust the antibody and the data they have generated in their studies.
View all MS Validated Antibodies Products
MS Validated Antibodies is devoted to delivering optimal monoclonal antibodies for immunohistochemistry and to provide the users with a unique product documentation enabling them to know as much as possible on their antibodies. Key features of the MSVA package include:
Highly stringent criteria for product selection: Only 135 out of the first 4500 evaluated antibodies were selected for the MSVA portfolio. - Unique product documentation including images from more than 50 different normal tissues and more than 20 tumor images per antibody.
Protocol suggestions for manual staining and autostainers (Dako, Leica, Ventana).
Published data on the performance characteristics of our antibodies are compiled on the MSVA homepage (if available).
Extensive educational content is provided for every antibody including links to other relevant sites.
Extensively validated, high-quality antibodies are key to successful experiments. Optimal antibodies are particularly critical for multiplex fluorescence immunohistochemistry where even one cross-reactive antibody can spoil an entire experiment.
MSVA Product Highlights
Want to know more about MSVA's flagship products?
See all the details and relevant citations here!
The enzyme S-methyl-5′-thioadenosine phosphorylase (MTAP) is of highest topical interest. Immunohistochemical detection of MTAP is very likely to become a frequent IHC application in surgical pathology because of its considerable diagnostic and predictive utility. A complete expression loss of MTAP occurs in up to 10% of all cancers. According to Gorbokon et al., MTAP IHC may thus substantially help to distinguish neoplastic from normal cells in case of suspected mesothelioma, urothelial dysplasia and carcinoma, pancreatic adenocarcinoma, lung cancer and other cancers. Because MTAP loss renders cells critically susceptible to several new cancer drugs, MTAP IHC may also support treatment decisions in the future.
Considerable research using MTAP IHC is currently ongoing to characterize the role of MTAP deficiency in various cancer types.
